By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.
Monday we opened the box on a peptide with no warning label, and met two villains working together: Cherry the Picker feeding the flattering fragment, Influencer Ivy selling the feeling built on top of it. Tuesday we sat taking in information from the room where the FDA’s advisory council actually argued about it, an eight to six vote, one abstention, and a pharmacist who was less worried about the yes than about what it actually covered. Wednesday we ran the whole claim through the Skeptic's Toolkit. Friday, the claims go on trial. Here’s the verdict.
Two claims went through the Skeptic's Toolkit. Two labels came back.
Claim 1: “BPC-157 is a safe, natural alternative to the medicine you're scared of.” Verdict: FEAR BAIT
Nobody disputes that an approved drug's warning label is long and frightening to read. That’s not evidence the drug is dangerous. It’s evidence someone was legally required to find and print every risk before it reached you. The peptide skips that requirement entirely, not because it’s safer, but because “research use only” was never a safety category to begin with. The whole pitch depends on you feeling the leaflet before you think about what is missing where there isn't one.
The one line to remember: a long warning label is proof of work, not proof of danger. A blank one just means nobody did the work to check, not that no side effects or adverse reactions exist.
Claim 2: “There's real science behind BPC-157, it's not just hype.” Verdict: NOT YET
There is a file. It’s just much thinner than the popularity suggests. The FDA's own review found no dose-response relationship in any of the four animal studies it examined, and exactly one human trial in the condition it actually evaluated, ulcerative colitis: a conference abstract, never published, that did not reach a statistically real result. The injectable and oral forms most people are actually using have never been tested for any indication in a real trial. NOT YET does not mean never. It means the file has to exist before anyone gets to call it settled.
The one line to remember: fifty million video views is not a sample size, and influencers saying something changed their mind when they’re being paid by affiliate links doesn’t either.
Seen in the wild: the blank label
This is the part you don’t get anywhere else. Every Friday we pin real examples of the week's tactic next to its verdict, so you can recognize it the next time it slides through your own feed. Here’s The Blank Label, live.
EXHIBIT A: screenshot of a real “wolverine compound” or “research grade” peptide post or reel.
EXHIBIT B: screenshot of a real post citing a single study or abstract as “the research” behind a peptide claim.
EXHIBIT C: a before-and-after or "optimized" lifestyle post using the same playbook.
EXHIBIT D: screenshot of a real post claiming peptides are restricted for profit, not safety, the FDA/big pharma "conspiracy" framing.
EXHIBIT E: screenshot of a real post or ad where a celebrity or influencer's appearance stands in for evidence of a peptide claim.
How we judged it (members' bench notes)
You don’t just get the ruling, you get the workings. This is the same lens I used in clinical research, from the benchtop to the trial site to the CRO: identity, dose, evidence, oversight, and naming. Here is the bench BPC-157 was scored on.
Identity, is it studied for the use it's sold for? No. FDA reviewed it for ulcerative colitis, using an enema. It is sold and injected for muscle and joint recovery, a use nobody in that room evaluated.
Dose control, is the amount measured and consistent? No dose-response relationship has been established in any of the four animal studies FDA examined. No standard dose exists for the way most people are actually taking it.
Evidence, how many humans, for how long? Five small studies across every use combined, the largest around 26 people. In the reviewed condition specifically: one abstract, never published, not statistically significant.
Oversight, who is watching after you take it? FDA's own conclusion: insufficient information to characterize the safety profile. A prescription drug has a clinician and a monitoring system. This has neither.
Naming, does the name promise more than the data delivers? “Wolverine compound” and “research use only” both do the same job. They sound like a rating. Neither one is. Add it up and you get FEAR BAIT and NOT YET.
The one question that catches the whole costume
What was actually tested, and is that what you're about to do? Ask it of the indication and the ulcerative colitis review falls away from the sore shoulder. Ask it of the dose and the four animal studies with no dose-response fall away from the vial in your hand. Ask it of the form and the enema trial falls away from the injection. One question, every mismatch, the whole costume.
The takeaway
Here is the whole issue in one breath: a vote is not a trial, and a trial that exists is not automatically the trial that matters to you. This peptide is not proven dangerous. It is also not proven anything close to what the feed is telling you. FEAR BAIT and NOT YET are not the same as guilty. They are the honest label for a compound that has been marketed far ahead of what anyone has actually checked. You do not have to swear off every unapproved compound. You do have to ask what was actually tested, before you decide it applies to you.
Ivy and Cherry lose this week. But the algorithm that rewards the loudest fragment over the fullest file does not answer to a committee vote. Monday, the box opens again, new tactic, same warning.
Black Box Warning. The strongest alert we can issue.
Want Thursday and Friday too?
The Informed (Thursday) and The Verdict (Friday) do not come automatically. You have to turn them on yourself. It takes ten seconds and it is the only way the full week lands in your inbox. Opt-in Instructions
Refer a friend
You just got the verdict that could protect someone you love. Hand it to them.
References
[1] FDA Briefing Document for BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (fda.gov/media/193343/download).
[2] Salzman, S. and Kekatos, M. “FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list.” ABC News, July 23, 2026.
[3] FDA, July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page (fda.gov/advisory-committees).
Try it yourself: see if you’d have caught this week's costume on your own.
The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type.
Got Skepticism? runs any claim through the same one-question move Sam just used.
Stay in the Room shows you how to disagree without a fight so that you can talk to people about these difficult topics.
The quiz and both games play in your browser at openlabelmedia.com, and I would love to see your results on social.
For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.
Instagram: instagram.com/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | TikTok: tiktok.com/@root.to.rx | YouTube: youtube.com/@roottorx | Threads: threads.com/@roottorx | Subscribe: RootToRx.com
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States